Gevo(GEVO) - 2025 Q3 - Earnings Call Transcript
2025-11-10 22:30
Gevo (NasdaqCM:GEVO) Q3 2025 Earnings Call November 10, 2025 04:30 PM ET Speaker2Good day, and thank you for standing by. Welcome to the Gevo Incorporated Third Quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw yo ...
VirTra(VTSI) - 2025 Q3 - Earnings Call Transcript
2025-11-10 22:30
Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $5.3 million, down from $7.5 million in the prior year period, primarily due to lower government sector revenues caused by funding delays [10] - Government revenue for Q3 was $4.1 million compared to $6.9 million in the prior year, while international revenue increased to $1.2 million from $0.4 million [10] - Gross profit for Q3 was $3.5 million, or 66% of total revenue, down from $5.5 million, or 73% in the prior year [10] - Net loss for Q3 was $0.4 million, or $0.03 per diluted share, compared to net income of $0.6 million, or $0.05 per diluted share in the prior year [12] Business Line Data and Key Metrics Changes - The STEP program remains a strong selling point, particularly for smaller agencies, driving consistent adoption and high renewal rates, contributing to recurring revenue [6] - The introduction of the V1 portable simulator is aimed at expanding the addressable market for smaller departments [7] - International revenue more than doubled compared to the same period last year, indicating growing global recognition of VirTra's training solutions [8] Market Data and Key Metrics Changes - The operating environment is affected by federal funding delays, with agency procurement cycles moving slower than normal due to budget clarity and grant awards [4] - The Department of Justice COPS Grants Program has identified agencies for funding, but announcements were delayed due to federal shutdowns [4] - Military work is progressing, with a successful demonstration of the Soldier Virtual Trainer system for the U.S. Army [8] Company Strategy and Development Direction - The company is focused on improving sales processes, products, and operations to strengthen its foundation and prepare for growth as funding resumes [15] - The recent entry into the GSA procurement cycle channel is expected to streamline sales processes and shorten delivery timelines [5] - The updated STEP program with three-year commitments enhances recurring revenue visibility and reinforces long-term customer relationships [14] Management's Comments on Operating Environment and Future Outlook - Management noted that while the operating environment is challenging due to funding delays, there is strong engagement with customers and a growing backlog of opportunities [3] - The company anticipates improved revenue conversions once grant awards and customer acceptance pick up [4] - Management expressed optimism about future growth as funding resumes and highlighted the importance of building relationships with military partners [9] Other Important Information - Cash and cash equivalents as of September 30, 2025, totaled $20.8 million, up from $18 million at the end of 2024 [13] - Backlog as of September 30, 2025, stood at $21.9 million, with $10.2 million in capital, $5.3 million in service, and $6.4 million in STEP contracts [14] Q&A Session Summary Question: Were there any multi-year deals that skewed booking results? - A booking of about $4.8 million was received at the end of the quarter, primarily from an international customer, which is expected to convert to revenue in 2026 [17] Question: How does the funding backdrop impact military prospects? - The funding shutdown affects both military and police agency businesses, with significant reliance on government funding [19] Question: Can you break down the backlog in terms of funded versus unfunded? - The backlog includes $10.2 million in capital, with conversion dependent on customer purchasing and readiness [22][24] Question: Is the company considering acquisitions or buybacks? - The company is strategically waiting for funding clarity before considering acquisitions, focusing on technologies that align with its core offerings [26] Question: What is the outlook for gross margins going forward? - Gross margins are expected to remain similar to current levels, with a potential slight decrease, aiming for a range between 60% and 65% [30]
Radiant(RLGT) - 2026 Q1 - Earnings Call Transcript
2025-11-10 22:30
Financial Data and Key Metrics Changes - For Q1 2026, the company reported net income of $1.293 million on revenues of $226.7 million, translating to $0.03 per share, a decrease of approximately 61.7% from $3.376 million on $203.6 million of revenues in Q1 2025 [8][9] - Adjusted EBITDA for Q1 2026 was $6.8 million, down 28.1% from $9.452 million in Q1 2025. Excluding a one-time bad debt expense of $1.3 million, adjusted EBITDA would have been $8.1 million, slightly above the previous quarter [3][9] Business Line Data and Key Metrics Changes - The growth in transportation revenues was primarily driven by acquisition efforts, with organic growth opportunities emerging in contract logistics, customs services, and technology services [3][4] - The Navigate platform is expected to be a significant driver of organic growth, enhancing visibility and decision-making for customers [4][6] Market Data and Key Metrics Changes - The company remains virtually debt-free, with net debt of approximately $2 million against a $200 million credit facility, indicating a strong financial position [5] - The acquisition of WePort in Mexico is seen as a strategic move to enhance capabilities in a key market, supporting existing and new customers [5][33] Company Strategy and Development Direction - The company aims to balance capital allocation through strategic acquisitions, stock buybacks, and investments in sales resources, particularly focusing on the deployment of Navigate technology [6][47] - The management emphasizes a disciplined approach to capital allocation and a durable business model to navigate the challenging freight environment [4][5] Management's Comments on Operating Environment and Future Outlook - The management acknowledges a difficult freight market, particularly for international business, but notes early signs of improvement in over-the-road brokerage pricing [20][21] - The company is optimistic about the potential of Navigate to drive organic growth and enhance customer engagement over the coming quarters [18][19] Other Important Information - The company executed a stock buyback program, acquiring $0.8 million of its stock in Q1 2026 and an additional $2.8 million post-quarter [5] - The management is exploring opportunities to recover some of the $1.3 million bad debt related to the First Brands bankruptcy, although clarity on this remains uncertain [33][35] Q&A Session Summary Question: How should we think about Navigate's deployment and customer adoption? - The management indicated that they are in the early stages of deploying Navigate, which has been integrated with their core technology stack, and they expect to see incremental organic growth from this offering in the coming quarters [12][14] Question: What are the expectations for the current quarter in the freight market? - The management noted that the freight market remains challenging, but they anticipate some improvements in brokerage operations and value-added services [20][21] Question: Can you provide updates on the WePort acquisition and the impact of First Brands bankruptcy? - The management expressed excitement about the WePort acquisition, highlighting its strategic importance in Mexico, and acknowledged the unexpected nature of the First Brands bankruptcy, while exploring potential recovery options [33][35]
Plug Power(PLUG) - 2025 Q3 - Earnings Call Transcript
2025-11-10 22:30
Plug Power (NasdaqCM:PLUG) Q3 2025 Earnings Call November 10, 2025 04:30 PM ET Speaker1Greetings and welcome to the Plug Power Third Quarter 2025 Earnings Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. You may be placed into question queue at any time by pressing Star 1 on your telephone keypad. As a reminder, this conference is being recorded. If anyone should require operator assistance, please press ...
Nanobiotix (NasdaqGS:NBTX) FY Conference Transcript
2025-11-10 22:30
Nanobiotix (NasdaqGS:NBTX) FY Conference November 10, 2025 04:30 PM ET Speaker1I'm good.Speaker035 questions.Speaker1I have tough questions for you. All right, so welcome to this fireside chat with Nanobiotix. We've saved the best for last today. With us today, we have Laurent Lévy, CEO. Welcome, Laurent. Thanks for joining us. Maybe, again, stepping back, just could you give us a quick overview of your technology? I know you have three different platforms that you have developed. Maybe describe those to us ...
Belite Bio(BLTE) - 2025 Q3 - Earnings Call Transcript
2025-11-10 22:30
Belite Bio (NasdaqCM:BLTE) Q3 2025 Earnings Call November 10, 2025 04:30 PM ET Speaker1Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio Q3 2025 earnings call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press star 9 to raise your hand and star 6 to unmute. I will now hand the call over to Julie Fallon. Please go ahead.Speaker2Good afternoon, e ...
Getty Images (GETY) - 2025 Q3 - Earnings Call Transcript
2025-11-10 22:30
Financial Data and Key Metrics Changes - Q3 2025 revenue was $240 million, a slight year-over-year decrease of 0.2% and 2% on a currency-neutral basis [4][9] - Adjusted EBITDA for the quarter was $78.7 million, down 2.4% reported and 4.4% on a currency-neutral basis, with a margin of 32.8% [4][16] - Free cash flow improved to $7.9 million compared to negative $1.8 million in Q3 2024 [17] - Total debt outstanding was $1.38 billion, with net leverage at 4.3 times, slightly up from 4.2 times in Q3 2024 [18] Business Line Data and Key Metrics Changes - Creative revenue was $144.9 million, up 8.4% year-on-year, driven by Premium Access revenue [11][12] - Editorial revenue was $89.3 million, down 3.7% year-on-year, primarily due to declines in news and sports [13] - Agency revenue declined 22% year-on-year, reflecting ongoing macro uncertainty [12][13] Market Data and Key Metrics Changes - Revenue growth in the Americas was 0.8% on a currency-neutral basis, while EMEA was down 4% and APAC down 10.8% [15] - Annual subscription revenue increased to 58.4% of total revenue, up from 52.4% in Q3 2024, with growth driven by Premium Access [10] Company Strategy and Development Direction - The company is focusing on AI initiatives, including partnerships for content licensing with technology platforms [5][25] - The merger with Shutterstock is a key strategic focus, with ongoing regulatory reviews impacting the timeline [6][19] - The company aims to enhance operational efficiency through AI deployment within its business functions [26] Management's Comments on Operating Environment and Future Outlook - Management noted headwinds from tough year-on-year comparisons due to a strong editorial calendar in Q3 2024 [9][21] - The company updated its full-year revenue guidance to $942 million-$951 million, reflecting a year-on-year growth of 0.3%-1.2% [21][22] - Management expressed optimism about the potential for AI-related revenue streams in the future [25] Other Important Information - The company is facing legal challenges, including a favorable ruling in a trademark infringement case against Stability AI [7][8] - SG&A expenses increased to $101 million, primarily due to SOX compliance efforts and ongoing litigation costs [15][16] Q&A Session Summary Question: Can you elaborate on Getty's key AI initiatives and their potential revenue impacts for 2026? - Management highlighted multiple licensing deals, including a confidential agreement with Perplexity, which could develop into a material revenue stream [24][25] Question: How are the corporate and media customer segments performing? - Media segment saw a 3% decline, particularly in broadcast and production, while corporate segment remains healthy with close to 100% retention [27][28] Question: What is the retention rate for Premium Access subscriptions? - Premium Access has the highest retention rates among subscriptions, remaining consistent over time [29][30] Question: What drove the sequential recovery in creative revenue? - The recovery was attributed to a normalization of revenue allocation between creative and editorial, along with a significant deal that provided upfront revenue recognition [32][34]
Peraso(PRSO) - 2025 Q3 - Earnings Call Transcript
2025-11-10 22:30
Financial Data and Key Metrics Changes - Total net revenue for Q3 2025 was $3.2 million, up from $2.2 million in the prior quarter and down from $3.8 million in Q3 2024 [19] - GAAP gross margin increased to 56.2% in Q3 2025 from 48.3% in the prior quarter and 47% in the same quarter a year ago [21] - Non-GAAP gross margin for Q3 2025 was also 56.2%, compared to 48.3% in the prior quarter and 61.7% in Q3 2024 [22] - GAAP operating expenses for Q3 2025 were $3 million, down from $4.5 million in Q3 2024 [22] - Non-GAAP net loss for Q3 2025 was $1.7 million or a loss of $0.28 per share, compared to a loss of $2.7 million or $0.98 per share in the prior quarter [23] Business Line Data and Key Metrics Changes - Revenue from millimeter wave products was $3 million in Q3 2025, compared to $2.2 million in the prior quarter and $0.1 million in Q3 2024 [20] - The increase in revenue was primarily driven by a favorable revenue mix of millimeter wave products and solutions [21] Market Data and Key Metrics Changes - The company noted a steady recovery in market demand and customer orders for its 60 GHz wireless solutions, particularly in the fixed wireless access market [6][7] - The company highlighted significant wins in fixed wireless access, including partnerships with Tachyon Networks and WeLink Communications [9][10] Company Strategy and Development Direction - The company is focusing on expanding its millimeter wave solutions into new markets, including tactical communications for military applications [11][12] - The management emphasized the versatility of its technology, which can support high-bandwidth video for edge AI applications [14][15] - The company is committed to disciplined expense management while driving growth in its millimeter wave product lines [19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of the renewed momentum in the fixed wireless access market [7] - The company expects total net revenue for Q4 2025 to be in the range of $2.8 million to $3.1 million based on current backlog [25] Other Important Information - The company had approximately $1.9 million in cash as of September 30, 2025, compared to $1.8 million as of June 30, 2025 [24] - The strategic review process is ongoing, with no new updates provided during the call [24] Q&A Session Summary Question: Can you provide more details on the new OEM announced? - The new OEM is a significant player in the space, and the company is optimistic about the opportunity, although specifics cannot be disclosed due to confidentiality [26][27] Question: What is the expected timeline for customer production schedules? - The typical engagement to mass production timeline is 9-12 months for fixed wireless, while new markets like military may take 12-15 months [29] Question: How should the market view the increase in inventory and accounts receivable? - The increase in accounts receivable was due to timing of sales, and inventory was built to meet anticipated demand for Q1 and Q2 [30][31] Question: What is the outlook for gross margin going forward? - The company aims to maintain gross margins around 50%, with some fluctuations based on product mix and inventory sales [32][33] Question: How long does it typically take for pre-production customers to contribute to revenue? - Once a customer reaches pre-production, it typically takes about three months before they start contributing meaningfully to revenue [34]
Mineralys Therapeutics(MLYS) - 2025 Q3 - Earnings Call Transcript
2025-11-10 22:30
Financial Data and Key Metrics Changes - The company ended Q3 2025 with cash, cash equivalents, and investments of $593.6 million, a significant increase from $198.2 million as of December 31, 2024, indicating strong liquidity to support operations into 2028 [16] - R&D expenses for Q3 2025 were $31.5 million, down from $54 million in Q3 2024, primarily due to the conclusion of the lorandirostat pivotal program [16][17] - Net loss for Q3 2025 was $36.9 million, a decrease from $56.3 million in Q3 2024, reflecting improved expense management [18] Business Line Data and Key Metrics Changes - The company is advancing its clinical programs, particularly lorandirostat, which has shown clinically meaningful reductions in systolic blood pressure across diverse patient populations [6][10] - The EXPLORE-CKD trial demonstrated a significant reduction in systolic blood pressure and a clinically meaningful reduction in urinary albumin-creatinine ratio, indicating potential renal protection [10] Market Data and Key Metrics Changes - The company is focusing on market access planning and payer engagement to ensure the value of lorandirostat is well understood, which is crucial for its commercial readiness [13] - The ongoing phase II EXPLORE-OSA trial aims to evaluate lorandirostat's efficacy in patients with obstructive sleep apnea and hypertension, with results expected in Q1 2026 [11] Company Strategy and Development Direction - The company is preparing for an NDA submission for lorandirostat, expected by the end of 2025 or early 2026, following positive pre-NDA feedback from the FDA [5][36] - The strategy includes expanding lorandirostat's profile to address comorbid conditions associated with hypertension, such as chronic kidney disease and obstructive sleep apnea [12][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the clinical data supporting lorandirostat as a best-in-class therapy for uncontrolled and resistant hypertension [14][64] - The company is optimistic about upcoming milestones, including the NDA submission and results from the EXPLORE-OSA trial, which could enhance the drug's profile [64] Other Important Information - The company has emphasized the importance of diverse patient representation in clinical trials, particularly for Black or African American populations, which are often underrepresented in hypertension studies [54] - The management highlighted the need for partnerships to maximize the value of lorandirostat, both in the U.S. and internationally [38][49] Q&A Session Summary Question: What would the systolic blood pressure reduction be without adjusting for discontinuations? - Management indicated that they have not performed that specific analysis, as it was not part of the study plan [20][21] Question: Have you looked at the day and night blood pressure differences in the Advanced HTN trial? - Management confirmed that they are comfortable with the 24-hour control and have measured blood pressure at trough, but have yet to publish nighttime data [26][28] Question: Can you provide more details on the pre-NDA feedback? - Management stated that there were no surprises in the feedback and expressed confidence in the data set prepared for submission [35][36] Question: What are your expectations for the open label extension trial? - Management noted that the trial is progressing well, with no surprises, and results will be published once the last subject completes the study [40] Question: How do you expect to leverage data from the EXPLORE-OSA trial? - Management aims to enhance lorandirostat's profile by demonstrating its benefits beyond blood pressure reduction, addressing related comorbidities [41] Question: What differences in efficacy do you see with lorandirostat in the African American population? - Management highlighted that over 50% of participants in the Advance HTN trial were Black or African American, showing that race does not determine response to lorandirostat [54][56]
Chegg(CHGG) - 2025 Q3 - Earnings Call Transcript
2025-11-10 22:30
Chegg (NYSE:CHGG) Q3 2025 Earnings Call November 10, 2025 04:30 PM ET Speaker1Ladies and gentlemen, greetings and welcome to the Chegg Q3 2025 earnings conference call. At this time, all participants are in listen-only mode. A brief Q&A will follow the formal presentation. If anyone should require operator assistance during the conference, please press * and 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Tracey Ford, Vice President ...